spacer
The Healthcare Sales & Marketing Network celebrates 23 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Healthcare Industry News:  Sagent Pharmaceuticals 

Biopharmaceuticals Oncology

 News Release - October 29, 2012

Sagent Pharmaceuticals Announces the Launch of Leucovorin Calcium for Injection

SCHAUMBURG, Ill., Oct. 29, 2012 -- (Healthcare Sales & Marketing Network) -- Sagent Pharmaceuticals, Inc. (SGNT) today announced the launch of Leucovorin Calcium for Injection, a folic acid derivative, and an adjuvant in antineoplastic agent therapy, in four latex-free and preservative-free vial presentations. According to IMS, for the 12 months ending June 2012, the US market for Leucovorin Calcium for Injection approximated $14 million. As with all products in Sagent's portfolio, Leucovorin features the company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

"Leucovorin, which has consistently been on both the American Society of Health System Pharmacists and Food and Drug Administration lists of drug shortages, is one of the first products which we will launch from our supply agreement with Zydus Cadila," stated Jeffrey Yordon, President, Chief Executive Officer and Chairman of the Board of Sagent. "We are excited to provide this important product to our customers."

About Leucovorin Calcium for Injection

Leucovorin Calcium for Injection is indicated for rescue after high-dose methotrexate therapy in osteosarcoma; to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists; in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible; and for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.

The package insert, available at www.sagentpharma.com, contains the indications, complete side effect profile, and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.

Source: Sagent Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

Search: Sagent Pharmaceuticals 
Search: Leucovorin 
Search: folic acid 
Healthcare Industry NewsFeed  


FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.